Nuvalent Inc NUVL

NAS: NUVL | ISIN: US6707031075   15/05/2025
71,00 USD (-0,03%)
(-0,03%)   15/05/2025

8 mei 2025 · Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results · Persbericht

29 april 2025 · Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor · Persbericht

23 april 2025 · Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting · Persbericht

1 april 2025 · Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum · Persbericht

25 maart 2025 · Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025 · Persbericht

13 september 2024 · Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655 · Persbericht

9 september 2024 · Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles · Persbericht

29 augustus 2024 · Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference · Persbericht

8 augustus 2024 · Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results · Persbericht

22 juli 2024 · Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor · Persbericht

16 juli 2024 · Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024 · Persbericht

11 juli 2024 · Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer · Persbericht

29 mei 2024 · Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference · Persbericht

16 mei 2024 · Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655 · Persbericht

9 mei 2024 · Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results · Persbericht

8 april 2024 · Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 · Persbericht

5 maart 2024 · Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024 · Persbericht

27 februari 2024 · Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results · Persbericht

27 februari 2024 · Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520 · Persbericht

12 februari 2024 · Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors · Persbericht

Mijn selecties